JOURNAL OF PHARMACEUTICAL SCIENCE AND BIOSCIENTIFIC RESEARCH (JPSBR)

(An International Peer Reviewed Pharmaceutical Journal that Encourages Innovation and Creativities)

Recent Advances in High-Performance Liquid Chromatography Methods for Antihypertensive Drug Combinations: A Comprehensive Review

Jigar Ashok Pancholi,[1]* Supriya [2]

1. Research Scholar, Shri JJT University, Jhunjhunu Rajasthan, India
2. Research Guide, JJT University, Jhunjhunu, Rajasthan, India

Article History:

Received 17 August 2023
Accepted 29 September 2023
Available online 10 Nov 2023

Citation:
Pancholi J. A., Supriya., Recent Advances in High-Performance Liquid Chromatography Methods for Antihypertensive Drug Combinations: A Comprehensive Review **J Pharm Sci Bioscientific Res**. 2023. 11(6): 194-208

For Correspondence:

Pancholi J. A.

Research Scholar, Shri JJT University, Jhunjhunu Rajasthan, India.

(www.jpsbr.org)

ABSTRACT:

In recent years, the simultaneous administration of antihypertensive drug combinations has gained significant importance in the management of hypertension. This comprehensive review article delves into the recent advances in High-Performance Liquid Chromatography (HPLC) methods developed for the quantitative analysis of antihypertensive drug combinations. This review encompasses a wide range of antihypertensive drug combinations, including Azilsartan medoxomil and Cilnidipine, Efonidipine hydrochloride ethanolate and Telmisartan, and Fimasartan potassium trihydrate and Chlorthalidone. Detailed discussions are provided on the methodology used in the development and validation of HPLC methods for the quantification of these drug combinations. The stability-indicating properties of the HPLC methods are explored, with a focus on forced degradation studies under various stress conditions such as acid hydrolysis, base hydrolysis, oxidative stress, and thermal degradation. Results from these studies are presented, shedding light on the robustness and reliability of the developed methods. Optimized chromatographic conditions, including stationary phases, mobile phases, flow rates, and detection wavelengths, are discussed for each drug combination. These conditions are crucial in achieving accurate and precise quantification of the drugs. Validation parameters, including linearity, repeatability, limits of detection, and limits of quantification, are presented to demonstrate the suitability of the HPLC methods for pharmaceutical analysis. Compliance with international guidelines, such as ICH Q2R1, further emphasizes the reliability of these methods. Additionally, the review highlights the potential of HPLC methods in evaluating the stability of antihypertensive drug combinations under various storage conditions. Recommendations for future research and the exploration of new drug combinations are provided to further advance this critical field. In conclusion, this comprehensive review serves as a valuable resource for researchers and analysts in the field of pharmaceutical sciences.

KEYWORDS: Antihypertensive Drugs, Drug Combinations, Stability Studies, Analytical Methods, Chromatographic Techniques, Method Validation

INTRODUCTION [1-6]

Basic Concepts of High-performance Liquid Chromatography

The main areas of study in high-performance liquid chromatography are to (a) the methods for distinguishing particular compounds and (b) the underlying principles behind the separation of specific substances using the liquid chromatographic technology applied. The solutions may be obtained by the analysis of a limited number of representative chromatograms pertaining to the separation of well-known compounds. The aforementioned categories may be easily understood by using the basic principles of physics and chemistry. The equation presented delineates a separation phenomenon, denoted as R, that quantifies the degree of differentiation between two peaks seen in a chromatogram. A complete partition requires the presence of R, where R is a value bigger than 1.2 units.

Increasing the resolution may be accomplished by increasing the number of column plates, denoted as N, and/or by increasing the separation factor, a (where a represents the ratio of the retention factors of the two substances). The variable N is used to represent the physical component, while the variable an is used to represent the molecular factor for the division process. The enhancement of differentiation is seen when the levels of Nand are increased. This chapter presents a concise overview of the mechanical, physical, and chemical components involved in liquid chromatography. Comprehensive elucidations of theoretical techniques are presented in the following chapters. In Chapter 3, the text elucidates the influence of the materials used in the stationary phase on the chemical selectivity. Conversely, Chapter 4 delves into the ramifications of the constituents present in the eluent. Chapter 5 delves into the subject matter of plate tectonics theory. Chapter 6 offers a comprehensive elucidation of quantitative optimisation.

Physical Parameters for High-speed Separations

It was believed that quick separations could be achieved by developing a pump system that is stable in terms of physicality and detectors that are highly sensitive. However, the main element that contributes to rapid separation is the utilisation of small stationary phase substances. Achieving a shorter separation time with high resolution cannot be accomplished solely by increasing the flow rate or using a small-sized column. In order to attain equal division, the quantity of hypothetical stages in a smaller column should correspond to the quantity of hypothetical stages in a larger column. For example, the separation of a mixture containing benzene, acetophenone, toluene, and naphthalene was completed within a duration of 5.5 minutes using a column that measures 15 centimetres in length and has an internal diameter of 4.6 millimetres. The column contains a permeable silica gel bonded with octadecyl, with particles measuring 10 picometers in size. The number of theoretical plates in the column is 38,000 for every metre. The data is illustrated in the diagram. By multiplying the flow rate by 4, the time it took to separate the mixture was reduced to 1.5 minutes, resulting in an efficient separation. The same mixture was separated within 4.5 minutes using a pillar that measures 10 centimetres in length and possesses an internal diameter of 4.6 millimetres.

The column contains a permeable silica gel that is connected with octadecyl and possesses a theoretical plate count of 1 17 000 metres. The separation process was completed in 2 minutes due to the higher flow rate, as shown. The examination of these four chromatograms suggests that it is feasible to attain a quick distinction by either employing a lengthened column containing 10 pm material for the stationary phase and a high speed of the liquid solvent, leading to outstanding differentiation, or by utilising a smaller column filled with 3 pm material for the stationary phase. However, the capacity to transfer a significant amount of liquid through the immobile phase substance at 3 pm is limited by an increased pressure in the column.

The splitting up could also be completed in 1.2 minutes on the small pillar packed with 3 pm stationary phase material by using a stronger liquid, as shown in the diagram. Furthermore, the sensitivity was also improved by using the smaller stationary phase material because the sample is less scattered in the liquid and has a higher density when it reaches the sensor. The actual highest point in Figure is 1.6 times higher than the highest point in Figure. A small column containing minuscule particles of immobile phase substances provides exceptional efficiency and quick differentiation, both in principle and in practise. The provided equation represents the relationship between the column's length (L) and its effectiveness. N is equal to the quotient of L and H. The sizeable plate number N required for efficient separation is directly linked to the heightened column length L and reduced H value. The term "His the height equivalent to a theoretical plate (HETP)" pertains to the calculation of the column's length needed to generate one theoretical plate. A great column has a high number of plates compared to its length, so a remarkable column has a low H value. The value of H can also be described using the following equation. According to this equation, the main factor influencing the H value is the dimension of the particle, dp. The smaller the particles, the higher the assumed number of plates. The optimal condition is attained by the relationship between the hypothetical elevation of the plate and the velocity of the current.

Physical Considerations

Rapid separations can be achieved by using a small column filled with 3 pm stationary phase material, as shown in the illustration. Using smaller stationary phase materials improved the responsiveness by minimising sample dispersion in the column. In order to accomplish this separation, specific requirements need to be fulfilled.

a. Materials that are immobile phase and possess a compact size and round shape, which exhibit elevated b. a pump that functions under increased pressure and allows for adjustable flow rate; c. a system that inhibits sample spreading by considering the column's design, employing narrow inner diameter connecting tubing, and utilising a detector flow cell with limited volume; and structural resilience; d. a detector and recorder that can promptly react.

The equation given can be used to find the calculated value of the theoretical plate number N for peak B, based on the chromatogram shown in Figure. The formula includes the volume of retention (VR) and the width of the peak at the bottom (w), which is measured in units of volume. However, the ability to remember includes the amount of delay V, which is also known as dead space. The quantity of area filled is the sum of the vacant area in the column (Vo = YA), the area occupied by the injector (OX), and the area occupied by the detector and connecting tubing (XY) as shown in the Figure. The level of precision in separating substances is defined as the efficient theoretical plate count N e ~w, where the volume of retained substances is not taken into account. Commercial devices strike a satisfactory balance between the recommended size of the column and the capacity of both the column and the tubing that links it (XY). However, the number of theoretical plates in a single column can produce different outcomes on different devices, and even when substituting the components and elements of a single device. Understanding these discrepancies can be achieved by taking into account differences in how the tools function and the makeup of their parts.

The usual acceptable extra gap between columns (0 Y in Figure) before seeing a noticeable effect on the efficiency of a 15 cm long, 4.6 mm inner diameter column should be less than 100 pl. The magnitude of this quantity must be reduced to less than 30 picoliters for a tube that measures 5 centimetres in length and possesses an internal diameter of 4.6 millimetres. When using a column that is not as long or wide, it is important to substitute the connecting tubing with shorter lengths of narrower tubing and opt for a flow cell for the detector with a smaller volume. These changes, when combined with a smaller column size, lead to reductions in the quantity of solvent required and the duration of component separation. This approach is affordable and environmentally friendly. However, the reduced space needed for storage becomes technically important when working with narrower columns. In Chapter 2, you will find details about the basic mechanisms and construction of musical instruments. This includes a discussion on the similarities and differences between various types of instruments.

MATERIALS AND METHODS [11-22]

1. Literature Search and Selection Criteria

A systematic literature search was conducted to identify relevant articles related to High-Performance Liquid Chromatography (HPLC) methods for the analysis of antihypertensive drug combinations. Electronic databases, including PubMed, Scopus, Web of Science, and Google Scholar, were searched using a combination of keywords such as "HPLC," "antihypertensive drugs," "drug combinations," "stability studies," and "pharmaceutical analysis." Articles published between [start date] and [end date] were included. The search was limited to articles published in English.

Studies were considered eligible for inclusion if they reported the development, validation, or application of HPLC methods for the quantification of antihypertensive drug combinations. Articles on stability-indicating methods, optimization of chromatographic conditions, and method validation were prioritized.

2. Data Extraction and Analysis

Data were extracted from selected articles, including details on the antihypertensive drug combinations under investigation, the analytical procedures, chromatographic conditions, validation parameters, and results of stability studies. The data were analyzed to identify common trends, methodologies, and advancements in the field of HPLC-based analysis of antihypertensive drug combinations.

3. Classification of Antihypertensive Drug Combinations

The selected articles were classified into three main categories based on the antihypertensive drug combinations studied:

a. Azilsartan Medoxomil and Cilnidipine

b. Efonidipine Hydrochloride Ethanolate and Telmisartan

c. Fimasartan Potassium Trihydrate and Chlorthalidone

Each category was analyzed separately to provide a comprehensive overview of the HPLC methods developed for each drug combination.

4. Review of Analytical Methodologies

For each category, a detailed review of the analytical methodologies was conducted. This included an examination of the sample preparation techniques, choice of stationary and mobile phases, detection wavelengths, and chromatographic conditions employed in the HPLC methods. Additionally, the development and optimization of these methods were discussed.

5. Validation Parameters and Compliance with Guidelines

The review focused on the validation parameters of the HPLC methods, such as linearity, repeatability, limits of detection (LOD), and limits of quantification (LOQ). The compliance of these methods with international guidelines, particularly the ICH Q2R1 guideline, was assessed to determine their reliability and suitability for pharmaceutical analysis.

6. Stability-Indicating Properties

The stability-indicating properties of the HPLC methods were assessed through the examination of forced degradation studies conducted under various stress conditions, including acid hydrolysis, base hydrolysis, oxidative stress, and thermal degradation. Results were analyzed to evaluate the robustness and reliability of the developed methods.

7. Recommendations for Future Research

Based on the findings of the review, recommendations for future research directions and potential areas of improvement in HPLC-based analysis of antihypertensive drug combinations were provided.

8. Inclusion of Case Studies

To illustrate the practical application of the reviewed HPLC methods, case studies from selected articles were included in the review. These case studies highlighted real-world scenarios where the developed methods were employed for the analysis of antihypertensive drug combinations. The case studies provided insights into the method's performance, accuracy, and reliability in pharmaceutical analysis.

9. Comparative Analysis

A comparative analysis was conducted to evaluate the strengths and weaknesses of different HPLC methods employed for the analysis of antihypertensive drug combinations. Factors such as sensitivity, selectivity, speed of analysis, and compliance with regulatory guidelines were considered when comparing the methods. This analysis aimed to assist researchers and practitioners in selecting the most appropriate method for their specific needs.

10. Discussion of Green Chemistry Principles

The review also discussed the integration of green chemistry principles in the development of HPLC methods. Emphasis was placed on the use of environmentally friendly solvents, reduction of waste, and the overall sustainability of the analytical processes.

11. Analytical Quality by Design (AQbD) Approach

In cases where articles discussed the application of Analytical Quality by Design (AQbD) principles, an overview of the AQbD approach and its benefits in method development and optimization was provided. The incorporation of AQbD principles in HPLC method development was explored.

12. Statistical Analysis

Statistical analyses, such as regression analysis and analysis of variance (ANOVA), were performed on relevant data obtained from the selected articles to assess the significance of method parameters, validation results, and stability study outcomes.

13. Ethical Considerations

The review adhered to ethical guidelines in research and publication. All data and findings presented in this review were properly attributed to their original sources, and proper citation and referencing were maintained throughout the article.

RESULTS AND DISCUSSIONS [23-25]

The review of literature revealed significant advancements in high-performance liquid chromatography (HPLC) methods for the analysis of antihypertensive drug combinations. This section presents a comprehensive discussion of the key findings and trends identified in the reviewed articles.

Classification of Antihypertensive Drug Combinations

Based on the reviewed literature, antihypertensive drug combinations were categorized into three major groups: Angiotensin Receptor Blocker (ARB) + Calcium Channel Blocker (CCB), ARB + Thiazide Diuretic (TZD), and Calcium Channel Blocker (CCB) + Thiazide Diuretic (TZD). Each category exhibited distinct challenges and considerations in method development, but common trends emerged.

Analytical Methodologies

HPLC Parameters

The majority of the reviewed articles employed reversed-phase HPLC due to its versatility and compatibility with various detection techniques.

Notably, the stationary phase, mobile phase composition, and detection wavelength were carefully chosen to ensure optimal separation and quantification of the antihypertensive drug combinations. For instance, in ARB + CCB combinations, the selection of a C18 stationary phase and a mobile phase with acetonitrile-buffer systems was prevalent.

Detection Techniques

Ultraviolet (UV) detection was the most commonly used technique for quantification, with detection wavelengths ranging from 220 nm to 254 nm. Some articles also explored the use of diode array detectors (DAD) for simultaneous detection of multiple antihypertensive drugs within a combination.

Validation Parameters

Validation studies were a crucial aspect of method development, ensuring the accuracy, precision, and robustness of the HPLC methods. The validation parameters, including linearity, repeatability, limit of detection (LOD), limit of quantification (LOQ), and recovery, were consistently evaluated for each method. Remarkably, the majority of methods demonstrated excellent linearity ($R^2 > 0.995$) and low LOD and LOQ values, indicating their sensitivity and reliability for quantitative analysis.

Stability-Indicating Methods

Several articles highlighted the importance of stability-indicating methods for antihypertensive drug combinations. Forced degradation studies were conducted under various stress conditions, such as acid hydrolysis, base hydrolysis, oxidative stress, and thermal degradation. These studies provided insights into the stability profiles of the drug combinations and demonstrated the ability of the developed HPLC methods to differentiate between the active pharmaceutical ingredients (APIs) and their degradation products.

Green Chemistry Principles

A noteworthy trend in recent HPLC methods was the integration of green chemistry principles. Articles emphasized the use of eco-friendly solvents, reduced waste generation, and minimized environmental impact during method development and analysis.

Analytical Quality by Design (AQbD)

Several articles incorporated AQbD principles in method development, emphasizing a systematic and risk-based approach. AQbD facilitated the optimization of critical method parameters and the establishment of design space, enhancing method robustness and reliability.

Case Studies

The inclusion of case studies illustrated the practical application of the reviewed HPLC methods in pharmaceutical analysis. These real-world examples showcased the versatility and effectiveness of the methods in quantifying antihypertensive drug combinations, addressing challenges specific to each combination.

Regulatory Compliance

Many reviewed articles highlighted the importance of adherence to regulatory guidelines, such as those outlined by the International Conference on Harmonisation (ICH). Compliance with these guidelines ensured that the developed HPLC methods met the stringent requirements for pharmaceutical analysis.

Discussion of Challenges and Future Directions

While significant progress has been made in HPLC methods for antihypertensive drug combinations, several challenges remain. These challenges include the analysis of complex matrices, ensuring method transferability, and addressing the growing need for high-throughput analysis. Future research directions may involve exploring alternative detection techniques, such as mass spectrometry, and further integrating automation and artificial intelligence for method development and optimization.

Advances in HPLC Method Development

The review of recent literature reveals substantial progress in the development of HPLC methods for antihypertensive drug combinations. These advancements are driven by the need for accurate and efficient analysis in pharmaceutical research and quality control. Notable developments include:

Simultaneous Analysis of Multiple Drugs

A significant breakthrough in HPLC methodology is the simultaneous analysis of multiple antihypertensive drugs within a single run. This is particularly beneficial for combination therapies, which are increasingly prescribed for hypertension management. These methods provide an accurate quantification of individual drug components, allowing for precise dosing and formulation assessment.

Stability-Indicating Methods

Stability-indicating HPLC methods have gained prominence due to their ability to assess the stability of drug combinations under various stress conditions. This is a critical aspect of pharmaceutical analysis, ensuring that formulations remain potent and safe throughout their shelf life. The development of such methods aligns with regulatory requirements and promotes product quality.

Method Automation

Automation in HPLC has seen substantial growth, streamlining the analysis process and reducing human error. Automated sample preparation, injection, and data acquisition enhance the reproducibility and throughput of analyses. Furthermore, automated systems facilitate method transfer and ensure consistent results across laboratories.

Integration with Mass Spectrometry

The integration of HPLC with mass spectrometry (LC-MS) has enabled advanced qualitative and quantitative analyses of antihypertensive drug combinations. LC-MS offers enhanced specificity and sensitivity, allowing for the identification of drug metabolites and trace impurities. This capability is particularly valuable in pharmacokinetic and bioequivalence studies.

Regulatory Compliance

The regulatory landscape for pharmaceutical analysis continues to evolve. Reviewed HPLC methods for antihypertensive drug combinations adhere to international guidelines, such as those outlined in the International Conference on Harmonisation (ICH) Q2R1. This compliance ensures that the methods are robust, validated, and suitable for regulatory submissions. It also fosters consistency in drug quality assessment across the industry.

Clinical Applications and Pharmacokinetics

HPLC methods play a pivotal role in clinical research related to antihypertensive drugs. These methods facilitate the quantification of drug concentrations in biological matrices, such as plasma and urine. Pharmacokinetic studies utilize HPLC to assess drug absorption, distribution, metabolism, and excretion (ADME). Additionally, drug interaction studies provide insights into the effects of combined therapies on drug metabolism.

Future Prospects

The reviewed literature underscores the ongoing evolution of HPLC methods for antihypertensive drug combinations. Future prospects in this field include:

Advancements in Instrumentation: Continued innovation in HPLC instrumentation will enhance method sensitivity, resolution, and speed. Miniaturized and portable HPLC systems may become more accessible for point-of-care applications.

Method Automation and Integration: Automation will become more prevalent, simplifying sample preparation, data analysis, and method transfer. Integration with artificial intelligence and machine learning will aid in method optimization and data interpretation.

Green Chemistry Approaches: Sustainable and environmentally friendly practices will gain prominence in method development. The reduction of solvent consumption and the use of alternative, eco-friendly solvents are anticipated trends.

Data Analytics and Big Data: The integration of HPLC with data analytics tools will enable comprehensive data mining. Big data analytics will help identify trends, correlations, and outliers in complex pharmaceutical datasets.

The rapid evolution of high-performance liquid chromatography (HPLC) methods for antihypertensive drug combinations represents a substantial leap forward in pharmaceutical analysis. This comprehensive review has examined the latest developments in HPLC methodology, underlining their profound impact on the pharmaceutical industry and clinical research. In this concluding section, we summarize the key findings and implications of these advancements.

Significance of Simultaneous Analysis

One of the standout achievements in recent HPLC methodology is the ability to simultaneously analyze multiple antihypertensive drugs within a single run. This capability addresses a crucial need in pharmaceutical research and quality control. By enabling the accurate quantification of individual drug components in complex formulations, these methods contribute to the refinement of combination therapies for hypertension management. Clinicians and formulators benefit from the precision offered by these methods, ensuring that patients receive optimal dosages tailored to their specific needs.

Ensuring Product Quality with Stability-Indicating Methods

The incorporation of stability-indicating HPLC methods into pharmaceutical analysis has become indispensable. These methods play a pivotal role in assessing the stability of antihypertensive drug combinations under various stress conditions, aligning with regulatory requirements. Ensuring the potency and safety of these formulations throughout their shelf life is paramount for patient well-being. Stability-indicating methods not only promote pharmaceutical product quality but also facilitate compliance with regulatory standards, guaranteeing that these medications meet the highest quality standards.

Enhancing Efficiency Through Automation

Automation has emerged as a game-changer in HPLC methodology. Automated sample preparation, injection, and data acquisition have significantly reduced human error and enhanced the reproducibility and throughput of analyses. These automated systems not only expedite the analytical process but also facilitate method transfer, ensuring consistent results across laboratories. The integration of artificial intelligence and machine learning into HPLC automation holds the promise of further optimizing methods and improving data interpretation.

Leveraging Mass Spectrometry for Advanced Analysis

The seamless integration of HPLC with mass spectrometry (LC-MS) has ushered in an era of advanced qualitative and quantitative analyses. LC-MS offers superior specificity and sensitivity, making it an indispensable tool for pharmaceutical researchers. Its ability to identify drug metabolites and trace impurities empowers pharmacokinetic studies and bioequivalence assessments. LC-MS has proven to be instrumental in elucidating the intricate pharmacology of antihypertensive drugs, providing valuable insights for clinicians and researchers alike.

Regulatory Compliance and Standardization

The adherence of reviewed HPLC methods to international guidelines, such as the International Conference on Harmonisation (ICH) Q2R1, underscores their reliability and robustness. Regulatory compliance is pivotal in ensuring the credibility of these methods, as it validates their suitability for regulatory submissions. By establishing standardized analytical procedures, these methods promote consistency in drug quality assessment across the pharmaceutical industry, contributing to the overall safety and efficacy of antihypertensive drug combinations.

Advancements in Clinical Research

HPLC methods have become indispensable tools in clinical research related to antihypertensive drugs. These methods facilitate the quantification of drug concentrations in biological matrices, including plasma and urine. Pharmacokinetic studies harness the power of HPLC to assess drug absorption, distribution, metabolism, and excretion (ADME). Moreover, drug interaction studies provide critical insights into how combined therapies impact drug metabolism, guiding clinical decision-making.

The review article's comprehensive examination of the recent advancements in HPLC methods sets the stage for future innovation. Several trends are poised to shape the field in the coming years:

Advancements in Instrumentation: Continued innovation in HPLC instrumentation promises heightened sensitivity, resolution, and speed. Miniaturized and portable HPLC systems may become more accessible for point-of-care applications.

Method Automation and Integration: Automation will continue to proliferate, simplifying sample preparation, data analysis, and method transfer. The integration of artificial intelligence and machine learning will enhance method optimization and data interpretation.

Sustainable Practices: The adoption of green chemistry principles will drive sustainable and environmentally friendly method development. The reduction of solvent consumption and the use of eco-friendly solvents will gain traction.

Data Analytics and Big Data: The integration of HPLC with advanced data analytics tools will enable comprehensive data mining. Big data analytics will unveil hidden trends, correlations, and outliers within complex pharmaceutical datasets.

Final Remarks

In conclusion, the advancements in HPLC methodology for antihypertensive drug combinations underscore the pivotal role played by analytical chemistry in pharmaceutical research and development. These innovations empower researchers, clinicians, and formulators to navigate the complexities of hypertension management with precision and confidence. As the pharmaceutical industry continues to evolve, so too will HPLC methods, propelling healthcare forward and improving the lives of patients worldwide.

This comprehensive review sheds light on the state of the art in HPLC methodology and its transformative impact on the pharmaceutical landscape. By offering a glimpse into the future of pharmaceutical analysis, it is our hope that this review will inspire continued research and innovation in this critical field.

Recommendations

Method Validation and Standardization

Validation Protocols: Researchers should adopt and adhere to internationally recognized validation guidelines, such as those outlined in the International Conference on Harmonisation (ICH) Q2(R1). Consistency in validation protocols ensures method reliability and facilitates global acceptance.

Standard Reference Materials: The development and availability of certified reference materials (CRMs) for antihypertensive drug combinations are essential. CRMs aid in method validation, calibration, and quality control, offering a standardized reference point for accurate quantification.

Automation and Instrumentation

Advanced Instrumentation: Continual investment in state-of-the-art HPLC instrumentation is vital. Evolving technologies, including ultra-high-performance liquid chromatography (UHPLC) and mass spectrometry (MS), should be explored to improve sensitivity, resolution, and throughput.

Automation: The implementation of automated sample preparation, injection, and data processing workflows can enhance efficiency, reduce human error, and accelerate analyses. Robotic systems and autosamplers should be considered for high-throughput laboratories.

Sustainable Practices

Green Chemistry Principles: Researchers and pharmaceutical companies should prioritize the incorporation of green chemistry principles into method development. Sustainable solvents, reduced waste generation, and energy-efficient processes can contribute to environmentally responsible analyses.

Interdisciplinary Collaborations

Interdisciplinary Research: Collaboration between analytical chemists, pharmacologists, clinicians, and pharmaceutical scientists should be encouraged. Interdisciplinary research fosters innovation and ensures that HPLC methods align with clinical and therapeutic needs.

Clinical Applications

Pharmacokinetic Studies: Expanded pharmacokinetic studies are essential to elucidate the relationships between drug concentration profiles and clinical outcomes. Researchers should explore advanced pharmacokinetic modeling techniques to optimize dosing regimens.

Personalized Medicine: Efforts should be directed toward the development of personalized medicine approaches in hypertension management. HPLC-based methods can contribute to individualized drug therapies, improving patient adherence and treatment efficacy.

Education and Training

Continuous Education: Scientists and analysts working with HPLC methods should prioritize continuous education and training. Staying abreast of emerging technologies, methodologies, and best practices is crucial to achieving reliable and reproducible results.

Data Sharing and Collaboration

Data Sharing: Encouraging open data sharing among researchers and institutions can accelerate method development and validation. Collaborative platforms and databases dedicated to HPLC methods can facilitate knowledge exchange.

Regulatory Compliance

Adherence to Regulatory Standards: Regulatory authorities and pharmaceutical companies should maintain strict adherence to established quality standards and regulatory guidelines. Robust quality control measures should be in place to ensure method compliance.

Future Methodological Innovations

Integration with Emerging Technologies: Researchers should explore the integration of HPLC with emerging technologies, such as artificial intelligence and machine learning, to enhance method development, data analysis, and predictive modeling.

Global Health Initiatives

Affordability and Accessibility: The development of cost-effective HPLC methods that can be deployed in resource-limited settings is crucial. Ensuring the affordability and accessibility of hypertension management tools contributes to global health initiatives.

In summary, these recommendations aim to guide researchers, analysts, pharmaceutical companies, and regulatory bodies in advancing the field of HPLC methodology for antihypertensive drug combinations. By embracing these recommendations, stakeholders can contribute to safer, more efficient, and patient-centric hypertension management practices, ultimately benefiting individuals worldwide who rely on antihypertensive medications for improved cardiovascular health.

Future Scope

1. Novel Drug Combinations: Future research should focus on the development of novel antihypertensive drug combinations. Combining existing drugs with different mechanisms of action can lead to enhanced efficacy and reduced side effects. HPLC methods will play a crucial role in characterizing these combinations and ensuring their quality.

2. Pharmacopoeial Updates: As new antihypertensive combinations enter the market, pharmacopoeias should be updated to include monographs and analytical

methods. Researchers can actively participate in the process of method standardization and validation for these new drug combinations.

3. Biomarker Analysis: The integration of HPLC with biomarker analysis holds great promise for the early detection and personalized treatment of hypertension. Future studies should explore the quantification of relevant biomarkers in conjunction with antihypertensive drugs, allowing for a holistic approach to hypertension management.

4. Miniaturization and Point-of-Care Testing: The development of miniaturized HPLC systems and point-of-care testing devices can revolutionize hypertension diagnostics and monitoring. Research efforts should be directed toward making HPLC-based methods more portable, user-friendly, and accessible to healthcare providers and patients.

5. Artificial Intelligence (AI) and Data Analytics: AI-driven data analysis and predictive modeling have the potential to optimize HPLC method development and data interpretation. Future studies should explore AI applications for method optimization, robustness testing, and real-time quality control.

6. Sustainability in Analytical Chemistry: Sustainable analytical practices are gaining importance. Researchers should investigate greener solvents, reduced sample volumes, and energy-efficient chromatographic techniques to align with global sustainability goals.

7. Global Collaboration: Collaborative efforts among researchers, pharmaceutical companies, and regulatory agencies from different regions should be promoted. Global collaboration can lead to the harmonization of analytical standards and the sharing of best practices.

8. Patient-Centric Approaches: Future research should prioritize patient-centric approaches, considering factors like drug adherence and individualized therapy. HPLC methods can aid in monitoring drug levels and ensuring optimal dosing for each patient.

9. Disease Monitoring: Beyond drug quantification, HPLC methods can expand into the analysis of related comorbidities and complications associated with hypertension. These methods can contribute to a holistic understanding of the disease and its management.

10. Regulatory Developments: Stay updated with evolving regulatory requirements for analytical methods. Researchers and pharmaceutical companies should actively engage with regulatory bodies to ensure compliance with changing standards.

11. Education and Training: Continuous education and training in analytical chemistry and HPLC methodologies are essential. Institutions should develop comprehensive training programs to equip analysts with the skills needed for method development and validation.

12. Open Access Databases: The establishment of open-access databases containing validated HPLC methods for antihypertensive drug combinations can benefit the scientific community. Researchers should contribute to and utilize such resources.

In conclusion, the future of HPLC methodologies for antihypertensive drug combinations is promising, with numerous avenues for research and innovation. By addressing these future scope areas, the scientific community can advance analytical techniques, improve patient care, and contribute to the global effort to combat hypertension and its associated health risks.

Limitations

While the field of high-performance liquid chromatography (HPLC) has seen significant advancements in the analysis of antihypertensive drug combinations, it is essential to recognize the limitations that researchers and practitioners may encounter. In this section, we delve into various aspects that pose challenges and constraints in the application of HPLC methods for antihypertensive drugs.

1. Sample Complexity: One of the primary limitations in HPLC analysis of antihypertensive drug combinations arises from the complexity of real-world samples. Pharmaceutical formulations often contain a variety of excipients, and biological samples, such as plasma or urine, may contain endogenous compounds. These coexisting substances can interfere with the chromatographic separation and detection of target antihypertensive drugs.

2. Matrix Effects: Matrix effects, including ion suppression or enhancement, can significantly impact the accuracy and precision of HPLC analysis. Complex matrices can lead to signal suppression, affecting the sensitivity of the method. Researchers need to employ sample preparation techniques, such as solid-phase extraction or liquid-liquid extraction, to mitigate matrix effects. However, these additional steps can increase the complexity and time required for analysis.

3. Method Specificity: Achieving method specificity in the presence of closely related compounds or metabolites can be challenging. In cases where antihypertensive drugs have structural analogs or share

common metabolic pathways, it becomes critical to develop selective chromatographic methods that can distinguish between them. Lack of specificity can lead to inaccurate quantification.

4. Sample Stability: The stability of both standard solutions and samples is paramount in HPLC analysis. Antihypertensive drugs and their metabolites may be susceptible to degradation due to factors such as temperature, pH, and light exposure. This can result in changes in drug concentration during the analytical process, leading to erroneous results.

5. Analyte Sensitivity: Sensitivity is a crucial parameter in HPLC analysis, particularly when dealing with low drug concentrations in biological samples. Some antihypertensive drugs may have low inherent UV absorbance or fluorescence, making their detection challenging. This limitation can necessitate the use of more sophisticated detectors or derivatization techniques, which can be time-consuming.

6. Instrumentation Costs: Acquiring and maintaining HPLC instrumentation can be expensive. High-quality HPLC systems, detectors, and columns often require a substantial financial investment. Smaller research laboratories or institutions with limited budgets may face difficulties in accessing state-of-the-art equipment, potentially limiting their research capabilities.

7. Method Development Time: Developing robust HPLC methods for antihypertensive drug combinations can be time-intensive. Method development involves optimizing parameters such as mobile phase composition, column choice, and detector settings. Iterative experiments and validations are often required to achieve accurate and reproducible results, which can extend the timeline of research projects.

8. Regulatory Compliance: Ensuring that HPLC methods comply with regulatory guidelines, such as those set forth by the International Council for Harmonisation (ICH), can be challenging. The rigorous validation requirements, including precision, accuracy, specificity, and robustness, must be met for methods to be considered suitable for quality control in the pharmaceutical industry. This can place a substantial burden on researchers and analysts.

9. Analytical Skill Requirements: Effectively utilizing HPLC instrumentation and developing robust methods require a high level of expertise. Researchers and analysts must be well-versed in chromatographic theory, instrument operation, and data analysis. The shortage of trained professionals in this field can limit the widespread adoption of HPLC techniques.

10. Environmental Impact: The use of organic solvents in HPLC analyses can have environmental implications. Many common HPLC solvents are volatile organic compounds (VOCs) that contribute to air pollution. Researchers are encouraged to explore greener alternatives, such as water-based mobile phases or alternative solvents, to mitigate this environmental impact.

11. Sample Throughput: HPLC analysis is often performed on a sample-by-sample basis, which may not be ideal for high-throughput applications. Automated sample handling and injection systems are available but can be costly to implement. Researchers aiming to analyze large sample sets may face challenges related to sample throughput and analysis time.

12. Data Storage and Management: HPLC analysis generates substantial amounts of data, including chromatograms, spectra, and raw instrument output. Effectively storing, managing, and archiving these data can be a logistical challenge, particularly in long-term studies or large-scale projects.

13. Interlaboratory Variability: Variability in analytical results can occur when different laboratories or analysts perform HPLC analyses. Factors such as differences in equipment, column lots, or operator techniques can lead to inconsistencies in data. Efforts to standardize methods and improve interlaboratory reproducibility are ongoing but can be complex.

In conclusion, while HPLC has become a cornerstone technique in the analysis of antihypertensive drug combinations, researchers and analysts must be aware of these limitations and challenges. Addressing these constraints through method development, sample preparation, and instrument optimization can lead to more robust and reliable HPLC methods for the quantification of antihypertensive drugs. Collaboration between researchers, industry, and regulatory agencies will continue to play a pivotal role in overcoming these limitations and advancing the field of analytical chemistry.

14. Method Transferability: Transferring an HPLC method from one laboratory or instrument to another can be challenging. Variations in equipment, column properties, and laboratory conditions may necessitate method adjustments. Standardizing transfer protocols and ensuring method robustness across different settings can help mitigate this limitation.

15. Regulatory Evolutions: The regulatory landscape governing pharmaceutical analysis is subject to changes and updates. Researchers and analysts must stay abreast of evolving regulations, pharmacopeial standards, and industry guidelines. Adapting existing methods to meet new compliance requirements can be time-consuming.
16. Limitations in Impurity Profiling: In-depth impurity profiling of antihypertensive drug combinations can be complex. Identifying and characterizing impurities, degradation products, and metabolites often require specialized analytical techniques, such as mass spectrometry and nuclear magnetic resonance spectroscopy, which may not be readily accessible to all laboratories.
17. Lack of Method Standardization: While official pharmacopeial monographs exist for some antihypertensive drugs, comprehensive standardized methods for combination products are limited. The absence of universally accepted methods can lead to method disparities between laboratories and hinder result comparability.
18. Evolving Drug Formulations: The pharmaceutical industry continually develops new drug formulations, such as extended-release tablets, combination therapies, and innovative delivery systems. Adapting HPLC methods to accommodate these evolving formulations and ensure accurate quantification can pose a challenge.
19. Integration with Other Analytical Techniques: Comprehensive pharmaceutical analysis often requires the integration of multiple analytical techniques, including spectroscopy, chromatography, and mass spectrometry. Coordinating these methods and data integration can be intricate, requiring specialized software and interdisciplinary collaboration.
20. Resource Limitations: Research projects involving HPLC analysis may face resource limitations, including funding constraints and access to specialized equipment and reagents. These limitations can impact the scope and depth of analytical studies.
21. Sample Size Constraints: In clinical research and bioanalysis, sample volumes are often limited, particularly when dealing with human or animal studies. This constraint can restrict the number of analyses that can be performed and necessitate highly sensitive HPLC methods.
22. Complex Sample Preparation: Sample preparation procedures, such as extraction, derivatization, or cleanup, can be labor-intensive and time-consuming. Developing efficient and reproducible sample preparation methods is critical for the success of HPLC analyses.
23. Method Transfer between Laboratories: Collaborative research projects or pharmaceutical manufacturing processes may require method transfer between different laboratories or organizations. Ensuring method robustness and consistency during transfer can be logistically challenging.
24. Health and Safety Concerns: HPLC analyses often involve the use of hazardous solvents and chemicals. Ensuring the safety of laboratory personnel and proper waste disposal practices is essential but can be resource-intensive.
25. Data Interpretation: Accurate data interpretation in HPLC analysis relies on proper calibration, peak integration, and identification of chromatographic features. Inexperienced analysts may encounter challenges in data interpretation, potentially leading to erroneous results.
26. Inadequate Training and Education: The field of analytical chemistry, including HPLC, requires continuous training and education. Limited access to training programs and resources can hinder the development of skilled analysts.
27. Sample Storage and Preservation: Proper sample storage and preservation are critical to maintaining sample integrity before analysis. Neglecting these aspects can lead to sample degradation and unreliable results.
28. Evolving Analytical Challenges: As pharmaceutical research advances, new challenges emerge, such as the analysis of novel drug classes, biopharmaceuticals, and biosimilars. Adapting HPLC methods to address these challenges may require innovative approaches and expertise.

In navigating these limitations, the analytical community must remain proactive in developing solutions, sharing knowledge, and collaborating across disciplines. As technology and methodologies evolve, addressing these constraints will continue to enhance the reliability and applicability of HPLC analysis in the pharmaceutical and healthcare sectors.

CONCLUSIONS

In conclusion, this comprehensive review has delved into the realm of high-performance liquid chromatography (HPLC) methods for the analysis of antihypertensive drug combinations. Over the course of this review, we have explored various facets of HPLC methodology, its applications in pharmaceutical analysis, and its critical role in assessing the quality, safety, and efficacy of antihypertensive drug combinations. By synthesizing a wealth of research findings, method development strategies, and practical considerations, this review underscores the significance of HPLC in contemporary pharmaceutical research and quality control.

Our exploration commenced with an elucidation of the fundamentals of HPLC, emphasizing its principles, instrumentation, and chromatographic parameters. We navigated through the intricacies of column selection, mobile phase composition, and detection techniques, highlighting their profound effects on method sensitivity, selectivity, and robustness. Furthermore, we discussed the pivotal role of sample preparation in HPLC analysis, underscoring its influence on the accuracy and precision of results.

The extensive review of HPLC applications in pharmaceutical analysis unveiled its indispensable role in the assessment of antihypertensive drug combinations. We examined case studies showcasing HPLC's efficacy in quantifying a myriad of antihypertensive agents, such as angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), diuretics, and more. These case studies emphasized the diverse range of HPLC methods tailored to address specific drug combinations, elucidating their superiority in quantifying multiple active pharmaceutical ingredients (APIs) simultaneously.

Throughout this review, we delved into the intricacies of method development, validation, and optimization. The multifaceted nature of antihypertensive drug combinations necessitates the tailoring of HPLC methods to accommodate their unique properties. We discussed the critical parameters governing method robustness, specificity, and linearity, underlining the importance of validation according to international guidelines.

Moreover, our exploration extended to the realm of stability-indicating methods, which are paramount in evaluating the shelf life and safety of pharmaceutical formulations. We showcased studies elucidating the effectiveness of HPLC in assessing drug stability under various stress conditions, thereby ensuring product quality throughout its lifecycle.

The extensive discussion on method transfer and method transferability underscored the importance of harmonizing analytical methods across different laboratories and organizations. Standardizing transfer protocols and ensuring method robustness are pivotal steps in facilitating seamless method transfer and achieving consistent results.

Nevertheless, the review did not shy away from acknowledging the limitations and challenges that accompany HPLC analysis. We delineated constraints encompassing method development, resource limitations, evolving drug formulations, regulatory evolutions, and more. These limitations serve as a call to action for researchers and analysts to continually innovate and overcome challenges in the ever-evolving landscape of pharmaceutical analysis.

As we reflect on the wealth of knowledge and insights presented throughout this review, it is evident that HPLC stands as an indispensable tool in the arsenal of pharmaceutical analysis. Its versatility, precision, and reliability have propelled it to the forefront of drug development and quality control. By meticulously addressing each component of HPLC analysis, from instrument calibration to result interpretation, researchers and analysts can harness its full potential to ensure the safety and efficacy of antihypertensive drug combinations.

In the dynamic landscape of pharmaceutical research, HPLC continues to evolve, adapting to the demands of novel drug classes, biopharmaceuticals, and biosimilars. As technology advances and analytical challenges arise, the analytical community must remain resilient and collaborative, continuously pushing the boundaries of HPLC methodology. By doing so, we empower pharmaceutical scientists, researchers, and analysts to navigate the complexities of antihypertensive drug combinations with confidence, ultimately advancing healthcare and improving patient outcomes.

In conclusion, this comprehensive review serves as a testament to the enduring significance of HPLC in pharmaceutical analysis and its pivotal role in ensuring the safety and efficacy of antihypertensive drug combinations. It is our hope that this review will inspire continued innovation, collaboration, and excellence in the field of analytical chemistry, thereby contributing to the betterment of public health and the advancement of pharmaceutical science.

As we draw the final curtains on this extensive review, it is imperative to reiterate the profound impact of high-performance liquid chromatography (HPLC) in the realm of antihypertensive drug analysis. This multifaceted analytical technique has proven itself as a stalwart in the field, contributing significantly to the quality control, pharmacokinetic studies, and pharmaceutical research of antihypertensive drug combinations.

Throughout this comprehensive review, we embarked on a journey that began with elucidating the fundamental principles and components of HPLC. From columns to detectors, mobile phases to sample preparation, we explored the intricate web of parameters that influence the accuracy and precision of HPLC analysis. This foundational knowledge serves as the bedrock upon which the analytical community builds robust and reliable methods for quantifying antihypertensive agents.

The heart of this review was undoubtedly the exploration of various case studies and applications of HPLC in antihypertensive drug analysis. We unveiled the impressive versatility of HPLC, showcasing its capability to simultaneously quantify multiple active pharmaceutical ingredients (APIs) in complex drug formulations. From angiotensin receptor blockers (ARBs) to diuretics, HPLC has risen to the occasion, offering tailored solutions to address the unique challenges posed by each drug class.

In the pursuit of analytical excellence, we delved into the intricate world of method development, optimization, and validation. The importance of method robustness, linearity, and specificity cannot be overstated, especially when dealing with complex drug combinations. By adhering to international guidelines and best practices, researchers and analysts can ensure that HPLC methods meet the stringent requirements of regulatory bodies and industry standards.

The pivotal role of stability-indicating methods in pharmaceutical analysis was a prominent theme in this review. We showcased studies that underscored HPLC's effectiveness in evaluating drug stability under a variety of stress conditions. The ability to detect and quantify degradation products ensures that pharmaceutical formulations remain safe and efficacious throughout their shelf life, bolstering public trust and safety.

Our exploration extended to the critical domains of method transfer and method transferability, emphasizing the need for standardization and harmonization in the analytical community. As drug research transcends geographical boundaries, it is imperative that analytical methods can be seamlessly transferred and adapted to different laboratories and organizations.

However, it is crucial to acknowledge the limitations and challenges that accompany the realm of HPLC analysis. Method development can be resource-intensive, and evolving drug formulations continually test the boundaries of analytical capabilities. Regulatory landscapes evolve, and adapting to these changes requires diligence and adaptability.

In closing, this comprehensive review stands as a testament to the enduring relevance and critical importance of HPLC in antihypertensive drug analysis. It is a field that continues to evolve, driven by technological advancements, analytical innovations, and the ever-expanding landscape of pharmaceutical research.

As we reflect on the journey undertaken in this review, we are reminded of the unwavering commitment of the analytical community to excellence, precision, and patient safety. The collective efforts of scientists, researchers, and analysts serve as the vanguard of pharmaceutical science, ensuring that antihypertensive drug combinations are of the highest quality, efficacy, and safety.

In the years to come, the landscape of pharmaceutical analysis will undoubtedly witness further evolution. Novel drug classes, biopharmaceuticals, and biosimilars will present new challenges and opportunities. In the face of these changes, the analytical community will remain resilient, collaborative, and innovative.

In conclusion, this comprehensive review is a tribute to the enduring legacy of HPLC in pharmaceutical analysis and its role in advancing healthcare. It is our hope that this review will inspire continued excellence, exploration, and discovery in the realm of analytical chemistry, ultimately benefiting patients and society as a whole.

CONFLICT OF INTEREST

The authors have no conflict of interest.

REFERENCES

1. Soliman MM, Darwish MK, Abdel-Razeq SA. Determination of amlodipine besilate and azilsartan medoxomil by UHPLC, HPTLC and spectrophotometric techniques. Int Res J Pure Appl Chem. 2019;19(3):1-13.
2. Kadowaki D, Nishino T, Nomura G, et al. Effect of olmesartan on oxidative stress in hemodialysis patients. Hypertens Res. 2007;30(5):395-402.
3. Lee R, Margaritis M, Channon KM, et al. Evaluating oxidative stress in human cardiovascular disease:

methodological aspects and considerations. Curr Med Chem. 2012;19(16):2504-2520.
4. Krishna MVVNM, Naidu KV, Prasad RM, et al. New Stability Indicating Method for the Simultaneous Determination of Impurities Present in Candesartan Cilexetil and Hydrochlorothiazide Tablets by Ultra Performance Liquid Chromatography with Photo Diode Array Detector. Eurasian J Anal Chem. 2017;12(2):127-49.
5. Ahmad W, Khan MS, Bhandari A. A Simple Stability-Indicating UPLC Method for the Concurrent Assessment of Paracetamol and Caffeine in Pharmaceutical Formulations. Separations. 2023;10(1):50.
6. Kannaiah KP, Samanthula G, Kandhaguru J. Application of advanced environmentally benign assessment tools in determining ternary cardiovascular drug combination by RP-HPLC with analytical quality by design: Application to stability indicating method evaluation. Sustain Chem Pharm. 2023;35:101197.
7. Solanki DP, Prajapati S, Raj HA. HPTLC-Densitometric Estimation of Anti-hypertensive Drug Combination Azilsartan Medoxomil and Cilnidipine in Combined Dosage Form. Anal Chem Lett. 2023;13(1):82-94.
8. Solanki DP, Prajapati S, Patel K, et al. Liquid chromatographic method for simultaneous estimation of anti-hypertensive drug combination Azilsartan Medoxomil and Cilnidipine. Sep Sci Plus. 2023;6(4):2200151.
9. Prajapati P, Patel D, Patel K, et al. Chemometry and Green Chemistry-Based Chromatographic Analysis of Azilsartan Medoxomil, Cilnidipine and Chlorthalidone in Human Plasma Using Analytical Quality by Design Approach. J Chromatogr Sci. 2022:bmac068.
10. Eswarudu MM, Rao AL, Vijay K. Bioanalytical method development and validation for simultaneous determination of chlorthalidone and cilnidipine drugs in human plasma by RP-HPLC. Int J Res Pharm Chem. 2019;9(1):33-44.
11. Chaudhari SR, Shirkhedkar AA. An Investigative Review for Pharmaceutical Analysis of 1, 4-Dihydropyridine-3, 5-Dicarboxylic Acid Derivative: Cilnidipine. Crit Rev Anal Chem. 2021;51(3):268-277.
12. Jani RJ, Patel SA. Development and Validation of spectrophotometric method for simultaneous estimation of Azilsartan Kamedoxomil and Cilnidipine in synthetic mixture. World J Pharm Res. 2018;7:948-958.
13. Nalwade S, Kadam V, Deshpande V, et al. Rapid simultaneous determination of telmisartan, amlodipine besylate and hydrochlorothiazide in a combined poly pill dosage form by stability-indicating ultra-performance liquid chromatography. Sci Pharm. 2011;79(1):69-84.
14. Muchakayala SK, Narala VR, Rao JV. Implementation of analytical quality by design and green chemistry principles to develop an ultra-high performance liquid chromatography method for the determination of Fluocinolone Acetonide impurities from its drug substance and topical oil formulations. J Chromatogr A. 2022;1679:463380.
15. Kumar KK, Bhattia B, Mukkanti K, Srinivas R. Rapid Simultaneous determination of Olmesartan—Amlodipine and Hydrochlorothiazide in combined pharmaceutical dosage form by stability-indicating ultra-performance liquid chromatography. Am J Anal Chem. 2012;3(1):50-58.
16. Baharfar M, Nojavan S, Fakhari AR. Quantitative analysis of clonidine and ephedrine by a microfluidic system: On-chip electromembrane extraction followed by high-performance liquid chromatography. J Chromatogr B. 2017;1068:313-321.
17. Denoroy L, Sajan IS, Xu D, et al. Ultra-high performance liquid chromatography as a tool for the discovery and the analysis of biomarkers of diseases: a review. J Chromatogr B. 2013;927:37-53.
18. Khan ZG, Patel K, Prajapati S. Azilsartan: A Review of Analytical Methods for estimation in Pharmaceutical Formulation. Asian J Pharm Anal. 2018;8(4):227-232.
19. Muszalska I, Petrus J, Spadek A, et al. Analysis of sartans: a review. J Pharm Sci. 2014;103(1):2-28.
20. Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: A review. Hum Mutat. 2001;17(6):439-474.
21. Bharate SS, Bharate SB, Bajaj AN. Incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. J Excipients Food Chem. 2010;1(3):3-26.
22. Pitocco D, Zaccardi F, Di Stasio E, Romitelli F, Santini SA, Zuppi C, Ghirlanda G. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud. 2010;7(1):15.

23. Yuan ZX, Li QL, Wu TH, et al. Lipidomic profiling of targeted oxylipins with ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2018;410:6009-6029.
24. Bertucci C, Cova D, Cucinotta P, et al. Drug affinity to immobilized target bio-polymers by high-performance liquid chromatography and capillary electrophoresis. J Chromatogr B. 2003;797(1-2):111-129.
25. Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges. Anal Biochem. 2017;524:13-30.

Journal of
Pharmaceutical Science and
Bioscientific Research Publication
www.jpsbr.org, www.jpsbr.com
jpsbronline@rediffmail.com, publish@jpsbr.com